J
James L. Troy
Researcher at Medical College of Wisconsin
Publications - 10
Citations - 2342
James L. Troy is an academic researcher from Medical College of Wisconsin. The author has contributed to research in topics: Bullous pemphigoid & Vemurafenib. The author has an hindex of 9, co-authored 10 publications receiving 2221 citations. Previous affiliations of James L. Troy include Veterans Health Administration.
Papers
More filters
Journal ArticleDOI
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
Fei Su,Amaya Viros,Carla Milagre,Kerstin Trunzer,Gideon Bollag,Olivia Spleiss,Jorge S. Reis-Filho,Xiangju Kong,Richard C. Koya,Keith T. Flaherty,Paul B. Chapman,Min Jung Kim,Robert Hayward,Matthew J. Martin,Hong Yang,Qiongqing Wang,Holly Hilton,Julie S. Hang,Johannes Noe,Maryou B K Lambros,Felipe C. Geyer,Nathalie Dhomen,Ion Niculescu-Duvaz,Alfonso Zambon,Dan Niculescu-Duvaz,Natasha Preece,Lidia Robert,Nicholas Otte,Stephen Mok,Damien Kee,Yan Ma,Chao Zhang,Gaston Habets,Elizabeth A. Burton,Bernice Wong,Hoa Nguyen,Mark M. Kockx,Luc Andries,Brian Lestini,K. B. Nolop,Richard J. Lee,Andrew K. Joe,James L. Troy,Rene Gonzalez,Thomas E. Hutson,Igor Puzanov,Bartosz Chmielowski,Caroline J. Springer,Grant A. McArthur,Jeffrey A. Sosman,Roger S. Lo,Antoni Ribas,Richard Marais +52 more
TL;DR: In this article, the authors performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib.
Journal ArticleDOI
A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180.
Zhi Liu,Luis A. Diaz,James L. Troy,James L. Troy,Ann F. Taylor,Daryl J. Emery,Janet A. Fairley,Janet A. Fairley,George J. Giudice +8 more
TL;DR: Subepidermal blistering associated with the human skin diseases bullous pemphigoid and herpes gestationis has been thought to be an IgG autoantibody-mediated process; however, previous attempts to demonstrate the pathogenicity of patientAutoantibodies have been unsuccessful.
Journal ArticleDOI
The role of complement in experimental bullous pemphigoid.
Zhi Liu,George J. Giudice,Susan J. Swartz,Janet A. Fairley,Janet A. Fairley,Gerd O. Till,James L. Troy,James L. Troy,Luis A. Diaz,Luis A. Diaz +9 more
TL;DR: It is demonstrated that anti-BP180 antibodies trigger subepidermal blistering in this BP model via complement activation, and this experimental model of BP should greatly facilitate future studies on the pathophysiology of autoantibody-mediated diseases of the dermal- Epidermal junction.
Journal ArticleDOI
A major role for neutrophils in experimental bullous pemphigoid
Zhi Liu,George J. Giudice,Xiaoye Zhou,Susan J. Swartz,James L. Troy,James L. Troy,Janet A. Fairley,Janet A. Fairley,Gerd O. Till,Luis A. Diaz,Luis A. Diaz +10 more
TL;DR: Findings provide the first direct evidence that neutrophils recruited to the skin via a C5-dependent pathway play an essential role in subepidermal blister formation in experimental BP, and suggest new directions for disease intervention.
Journal ArticleDOI
Analysis of Dermatologic Events in Vemurafenib-Treated Patients With Melanoma
Mario E. Lacouture,Madeleine Duvic,Axel Hauschild,Victor G. Prieto,Caroline Robert,Dirk Schadendorf,Caroline C. Kim,Christopher McCormack,Patricia L. Myskowski,Olivia Spleiss,Kerstin Trunzer,Fei Su,B. Nelson,K. B. Nolop,Joseph F. Grippo,Richard J. Lee,Matthew J. Klimek,James L. Troy,Andrew K. Joe +18 more
TL;DR: Dermatologic AEs associated with vemurafenib treatment in patients with melanoma were generally manageable with supportive care measures.